Radiographic pattern of progression of recurrent GBM treated with bevacizumab with or without irinotecan.

被引：0
|
作者：
Dory-Lautrec, P. [1 ]
Tabouret, E. [1 ]
Barrie, M. [1 ]
Boucard, C. [1 ]
Matta, M. [1 ]
Autran, D. [1 ]
Girard, N. [1 ]
Chinot, O. L. [1 ]
机构：
[1] Univ Hosp Timone, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2091
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2091
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
    Sathornsumetee, Sith
    Cao, Yiting
    Marcello, Jennifer E.
    Ii, James E. Herndon
    McLendon, Roger E.
    Desjardins, Annick
    Friedman, Henry S.
    Dewhirst, Mark W.
    Vredenburgh, James J.
    Rich, Jeremy N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) : 271 - 278
  • [32] Peritumoral Apparent Diffusion Coefficient as a Metric of Response in Patients with Recurrent Glioblastoma Multiforme Treated with Bevacizumab and Irinotecan
    Andre, J. B.
    Lu, S.
    Spearman, K.
    Raval, S. N.
    NEURORADIOLOGY JOURNAL, 2008, 21 (03): : 350 - 361
  • [33] FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan
    Colavolpe, Cecile
    Chinot, Olivier
    Metellus, Philippe
    Mancini, Julien
    Barrie, Maryline
    Bequet-Boucard, Celine
    Tabouret, Emeline
    Mundler, Olivier
    Figarella-Branger, Dominique
    Guedj, Eric
    NEURO-ONCOLOGY, 2012, 14 (05) : 649 - 657
  • [34] Prognostic value of CD109+circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan
    Eoli, M.
    Calleri, A.
    Bruzzone, M. G.
    Anghileri, E.
    Pellegatta, S.
    Mancuso, P.
    Di Stefano, A.
    Bertolini, F.
    Cuppini, L.
    Finocchiaro, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S21 - S21
  • [35] Prognostic Value of CD109+Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
    Cuppini, Lucia
    Calleri, Angelica
    Bruzzone, Maria Grazia
    Prodi, Elena
    Anghileri, Elena
    Pellegatta, Serena
    Mancuso, Patrizia
    Porrati, Paola
    Di Stefano, Anna Luisa
    Ceroni, Mauro
    Bertolini, Francesco
    Finocchiaro, Gaetano
    Eoli, Marica
    PLOS ONE, 2013, 8 (09):
  • [36] MCQs on "Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment"
    Darling, H. S.
    Jaiswal, Pradeep
    Lohia, Nishant
    Tiwari, Nishant R.
    INDIAN JOURNAL OF CANCER, 2021, 58 (01) : 96 - 97
  • [37] Baseline FET-PET kinetic pattern predicts outcome in recurrent GBM patients prior to bevacizumab therapy
    Horky, Laura
    Reardon, David
    Huang, Raymond
    Kijewski, Marie
    Wen, Patrick
    Gerbaudo, Victor
    Semer, James
    Sticka, William
    Strader, Christopher
    Park, Mi-Ae
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [38] Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
    Whitney B. Pope
    Xin Joe Qiao
    Hyun J. Kim
    Albert Lai
    Phioanh Nghiemphu
    Xi Xue
    Benjamin M. Ellingson
    David Schiff
    Dawit Aregawi
    Soonmee Cha
    Vinay K. Puduvalli
    Jing Wu
    Wai-Kwan A. Yung
    Geoffrey S. Young
    James Vredenburgh
    Dan Barboriak
    Lauren E. Abrey
    Tom Mikkelsen
    Rajan Jain
    Nina A. Paleologos
    Patricia Lada RN
    Michael Prados
    Jonathan Goldin
    Patrick Y. Wen
    Timothy Cloughesy
    Journal of Neuro-Oncology, 2012, 108 : 491 - 498
  • [39] Bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM): Results of a retrospective cohort study of the OMIT Bretagne and Pays de la Loire.
    Grude, F.
    Campone, M.
    Frenel, J.
    Soulie, P.
    Vauleon, E.
    Hadjarab, Y.
    Ganem, G.
    Denis, F.
    Egreteau, J.
    Lortholary, A.
    Porneuf, M.
    Simon, H.
    Hieu, P. D. A. M.
    Klein, V.
    Dominique, B.
    Deguiral, P.
    Desclos, H.
    Menei, P.
    Traore, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
    Pope, Whitney B.
    Qiao, Xin Joe
    Kim, Hyun J.
    Lai, Albert
    Nghiemphu, Phioanh
    Xue, Xi
    Ellingson, Benjamin M.
    Schiff, David
    Aregawi, Dawit
    Cha, Soonmee
    Puduvalli, Vinay K.
    Wu, Jing
    Yung, Wai-Kwan A.
    Young, Geoffrey S.
    Vredenburgh, James
    Barboriak, Dan
    Abrey, Lauren E.
    Mikkelsen, Tom
    Jain, Rajan
    Paleologos, Nina A.
    Lada, Patricia
    Prados, Michael
    Goldin, Jonathan
    Wen, Patrick Y.
    Cloughesy, Timothy
    JOURNAL OF NEURO-ONCOLOGY, 2012, 108 (03) : 491 - 498
12345